# US 2025/0367192 A1 · Bicyclic compounds and methods for their use in treating pitt hopkins syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367192 A1
- Document ID: US20250367192A1
- Status: Published application
- Kind: A1
- Application number: 19/303,146
- Filed: 2025-08-18
- Published: 2025-12-04
- Earliest claimed: 2019-10-22
- Assignees: Neuren Pharmaceuticals Limited
- Applicants: Neuren Pharmaceuticals Limited
- Inventors: Patricia COGRAM; Jonathan PILCHER; Lawrence Irwin GLASS
- Web page: https://patentgrep.com/patent/US20250367192A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/212: {IFN-alpha}
- A61K 38/215: {IFN-beta}
- A61K 38/217: {IFN-gamma}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

## Claims

### Claim 1

A method for treating a mammal having Pitt Hopkins Syndrome, comprising administering to the mammal, a compound having the formula:
or a pharmaceutically acceptable salt or hydrate thereof, wherein
X1 is selected from the group consisting of NR′, O and S;
X2 is selected from the group consisting of CH2, NR′, O and S;
R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O) R′, —C(O) OR′, —C(O) NR′R′, —C(NR′) NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6.

### Claim 2 (depends on 1)

The method of claim 1, where R1=methyl.

### Claim 3 (depends on 1)

The method of claim 1, where R1=allyl.

### Claim 4 (depends on 1)

The method of claim 1, where R2=R3=methyl and X2=S.

### Claim 5 (depends on 1)

The method of claim 1, where R1=allyl, R2=R3=R4=R5=H, X1=NH, X2=CH2.

### Claim 6 (depends on 1)

The method of claim 1, where R1=methyl, R2=R3=H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1=NH, X2=CH2.

### Claim 7 (depends on 1)

The method of claim 1, where R1=methyl, R2=R3=H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1=NH, X2=CH2.

### Claim 8 (depends on 1)

The method of claim 1, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, or in a gel.

### Claim 9 (depends on 1)

The method of claim 1, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient and a binder.

### Claim 10 (depends on 1)

The method of claim 1, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, or in a capsule.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering at least one anti-apoptotic compound, anti-necrotic compound, neuroprotective agent or an anti-inflammatory agent.

### Claim 12 (depends on 11)

The method of claim 11, where the anti-apoptotic compound, anti-necrotic compound, or neuroprotective agent is selected from the group consisting of insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3, FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependant neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue (ORG 2766), dizolcipine [MK-801], selegiline, NPS1506, GV1505260, MK-801, GV150526, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo (f) quinoxaline (NBQX), LY303070, LY300164, and the anti-MAdCAM-1 antibody MECA-367.

### Claim 13 (depends on 1)

The method of claim 1, wherein said compound is cG-2-AllylP.

### Claim 14 (depends on 1)

The method of claim 1, wherein said compound is cyclic cyclohexyl-G-2MeP.

### Claim 15 (depends on 1)

The method of claim 1, wherein said compound is cyclic cyclopentyl-G-2MeP.

### Claim 16 (depends on 1)

The method of claim 1, wherein said treatment produces an improvement in a symptom of the disorder as assessed using one or more clinical tests selected from the group consisting of Aberrant Behavior Checklist Community Edition (ABC), Vineland Adaptive Behavior Scales, Clinical Global Impression of Severity (CGI-S), Clinical Global Impression Improvement (CGI-I), the Caregiver Strain Questionnaire (CSQ), electroencephalogram (EEG) spike frequency, overall power in frequency bands of an EEG, hemispheric coherence of EEG frequencies, stereotypic hand movement, eye tracking, QTc variability, heart rate variability (HRV), respiratory irregularities, and abnormal coupling of cardiac and respiratory function compared to control animals not suffering from said disorder.

### Claim 17 (depends on 1)

The method of claim 1, where said treatment reduces at least one symptom selected from the group consisting of anxiety, depression, cognitive impairment, cognitive dysfunction, memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, abnormal nocturnal behavior, seizure activity, abnormal locomotion, abnormal expression of Phospho-ERK1/2, abnormal expression of Phospho-Akt, and bradycardia.

### Claim 18

A composition for treating a symptom of Pitt Hopkins Syndrome in a mammal suffering from such a disorder, comprising a compound having the formula:
or a pharmaceutically acceptable salt or hydrate thereof, wherein
X1 is selected from the group consisting of NR′, O and S;
X2 is selected from the group consisting of CH2, NR′, O and S;
R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O) R′, —C(O) OR′, —C(O) NR′R′, —C(NR′) NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6.

### Claim at position 19

19-34. (canceled)

### Claim 35 (depends on 1)

The method of claim 1, where the dose of the compound is from about 0.001 mg/kg to about 600 mg/kg.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein said animal or mammal is a human being.
